<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04226001</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0022</org_study_id>
    <secondary_id>2019-A00074-53</secondary_id>
    <nct_id>NCT04226001</nct_id>
  </id_info>
  <brief_title>Impact of a Carrier (Infection, Colonization) of Highly Bacteria Resistance on the Patient's Quality of Life Hospital Environment</brief_title>
  <acronym>QALYBHRe</acronym>
  <official_title>Impact of a Carrier (Infection, Colonization) of Highly Bacteria Resistance on the Patient's</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The quality of life of carriers detected infected or colonized by emerging highly resistant&#xD;
      bacteria (BHRe) following the implementation of specific hygiene measures during the&#xD;
      discovery of the microorganism has been little studied. To date, there have been no studies&#xD;
      to determine the quality of life (QoL) in France of patients with hospitalized HBHRD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Coordinator departure&#xD;
  </why_stopped>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of the implementation of Complementary Hygiene Precautions following a carrier of emerging highly resistant bacteria on the quality of life of hospitalized patients</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of the decrease in utility corresponding to the deterioration of the QOL of patients since the implementation of the Additional Hygiene Precautions (PCH) following the discovery of their emerging highly resistant bacteria (BHRe).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients screened for carriers infected or colonized by emerging highly resistant bacteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life questionnaire</intervention_name>
    <description>Quality of life questionnaire</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients infected or colonized by emerging highly resistant bacteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years old&#xD;
&#xD;
          -  Have a positive BHRe screening during the hospital stay and / or have a positive BHRe&#xD;
             clinical sample during the hospital stay&#xD;
&#xD;
          -  Conscious patients&#xD;
&#xD;
          -  All types of stays in the hospital sector&#xD;
&#xD;
          -  All pathologies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known patients with BHRe before hospitalization&#xD;
&#xD;
          -  PCH immediately upon admission (history of hospitalization abroad, patients contacted&#xD;
             during a previous hospitalization)&#xD;
&#xD;
          -  Cognitive problem&#xD;
&#xD;
          -  Patients not proficient in French (requiring an interpreter)&#xD;
&#xD;
          -  Patients under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David NARBEY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

